NASDAQ · Biotechnology

Pasithea Therapeutics Corp. (KTTA) Stock

$0.47 +6.03% NASDAQ: KTTA Healthcare

Valuation

MetricValue
Price$0.47
Market Cap$15.62M
P/E Ratio-0.19
P/B Ratio0.07
P/S Ratio0.00
EPS (TTM)$-2.91
52-Week High$2.06
52-Week Low$0.28
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.49%
ROA-41.18%
ROCE-48.04%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio11.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-5.0M$-13.0M$-16.0M$-14.0M$-21.0M
Net Profit$-2.0M$-14.0M$-16.0M$-14.0M$-20.0M
EPS$-4.20$-10.34$-13.01$-12.69$-2.91
Op Margin-29925.7%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$53.0M$45.0M$26.0M$16.0M$60.0M
Total Liabilities$2.0M$3.0M$3.0M$1.0M$5.0M
Cash$53.0M$33.0M$16.0M$7.0M$55.0M
Borrowings$0$1.0M$0$0$0

Latest News

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit GlobeNewswire · Jul 8, 2026 Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity MT Newswires · Jun 30, 2026 Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion GlobeNewswire · Jun 30, 2026 Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment MT Newswires · Jun 16, 2026 Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial GlobeNewswire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-14.0M$-13.0M$-14.0M$-15.0M
Investing Cash Flow$0$-3.0M$0$0$0
Financing Cash Flow$6.0M$-3.0M$-4.0M$0$0
Net Cash Flow$53.0M$-20.0M$-17.0M$-9.0M$48.0M
Free Cash Flow$-3.0M$-14.0M$-13.0M$-14.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA1958.97
FCF Yield-111.80%
Quick Ratio26.25
Interest Coverage0.00
Return 1Y-30.22%
Return 3Y-94.87%
Return 5Y—

Ownership

Insiders Held1.11%
Institutions Held70.34%
Institutions Float Held71.13%
Institutional HolderSharesReport Date
Adage Capital Partners GP L.L.C.2,100,0002026-03-31
Squadron Capital Management LLC2,100,0002026-03-31
Vivo Capital, LLC2,100,0002026-03-31
Janus Henderson Group PLC2,100,0002026-03-31
Ameriprise Financial, Inc.1,350,8962026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is led by CEO Tiago Reis Marques, employs 4 people, headquartered in US, publicly traded since 2021.

Pasithea Therapeutics Corp. (KTTA) stock trades at $0.47 with a market capitalization of $15.62M. The stock is valued at a price-to-earnings (P/E) ratio of -0.19, price-to-book of 0.07, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.28 and $2.06, and currently trades 77.2% below its 52-week high.

On profitability, Pasithea Therapeutics Corp. generates a return on equity (ROE) of -49.49%, return on capital employed of -48.04%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides